CEACAM6 as a machine learning derived immune biomarker for predicting neoadjuvant chemotherapy response in HR+/HER2- breast cancer.
Source check: Source checked. Not independent scientific confirmation.
Finding / tested result: Methods 2.1: 956 HR+/HER2− GEO cases, five train/four test datasets; Results: 10-algorithm analysis, NeuralNet AUC .816; retrospective 106-patient cohort and paired IHC n=9. Biomarker association, no proven treatment benefit.
Technology: Machine-learning classifiers rank CEACAM6-related features and evaluate association with neoadjuvant chemotherapy response.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning classifiers rank CEACAM6-related features and evaluate association with neoadjuvant chemotherapy response.
- Limitation / still unknown
- Results are limited to the reported models, cohorts, datasets or experiments; broader generalization and clinical or operational benefit were not established.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2025.1662004/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.